bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength?
by Zacks Equity Research
Seattle Genetics (SGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of -6.67% and 73.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More
by Zacks Equity Research
Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.
Zacks.com featured highlights include bluebird bio, Pros Holdings and Norwegian Cruise Line
by Zacks Equity Research
bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.
3 Stocks to Keep an Eye on for Superb Earnings Acceleration
by Tirthankar Chakraborty
Stocks like bluebird bio (BLUE), Pros Holdings (PRO), and Norwegian Cruise Line (NCLH) are worth a watch now because of solid earnings acceleration.
bluebird (BLUE) Stock Dives on Public Offering of Common Stock
by Zacks Equity Research
bluebird (BLUE) to issue secondary shares, diluting its current shareholder base. The company plans to raise $120 million in gross proceeds from this issue.
bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook
by Zacks Equity Research
bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More
by Ekta Bagri
Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.
Implied Volatility Surging for bluebird bio (BLUE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to bluebird bio (BLUE) stock based on the movements in the options market lately.
bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA
by Zacks Equity Research
bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.
bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH
by Zacks Equity Research
bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.
Why Is Bluebird (BLUE) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale
by Zacks Equity Research
bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.
bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals
by Zacks Equity Research
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.
bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.
Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fstar Therapeutics, Inc. (FSTX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Fstar Therapeutics, Inc. (FSTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations
by Zacks Equity Research
Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.
bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line
by Zacks Equity Research
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.